Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

Fig. 4

A Pharmacokinetics was calculated using PKSolver non-compartmental analysis software and demonstrated nDCB is long-circulating. B Tumor volume over time represents disease progression for up to 19 days; *p < 0.05; **p < 0.01; ***p < 0.001 vs. nDCB:nTLZ. C Overall survival demonstrated nDCB:nTLZ extends survival; *p < 0.05 vs. nDCB:nTLZ

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us